

Barcelona, October 21st 2019

SIGNIFICANT EVENT

Almirall: to receive \$100 MM milestone from the agreement with AstraZeneca

Almirall, S.A. (“ALM”), in accordance with the Spanish Securities Markets Law, notifies the following:

New AstraZeneca Milestone

Last April 1st 2019, the FDA approved Duaklir® based on the positive results of the AMPLIFY study which demonstrated significant improvements in lung function in patients with moderate to severe COPD, compared to each individual component (either acclidinium bromide or formoterol).

Almirall has granted AstraZeneca the licensing rights in the US of Duaklir®, a fixed-dose LAMA / LABA combination of the long-acting muscarinic antagonist (LAMA) aclidinium and long-acting beta-agonist (LABA) formoterol administered twice-daily via the breath-actuated, multi-dose inhaler Pressair®, relating to the agreement that was announced on November 3rd, 2014. Part of that agreement states that AstraZeneca will pay Almirall 100 million US dollars when the first commercial sales takes place in the US. Duaklir® will be available in the United States from 21st October.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com